Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Apatinib in locally advanced oral squamous cell carcinoma
NCT04393506Phase 1Completed
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Apr 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camrelizumab and Rivoceranib in oral squamous cell carcinoma (OSCC), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoints: Major Pathologic Response at 1 year and Safety and Tolerability at 1 year. Started Apr 2020; status: completed.
02
Drugs
camrelizumabRivoceranib
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT04393506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04393506.